ArticleNature communications2026
Steric Gating Contributes to the Preferential Ubiquitin Charging of BIRC6 by UBA6 versus UBA1.
Zebin Tong, Rujing Yuan, Xiangwei Wu, Hongyi Cai, Ziyu Xu, Lei Liu, Huasong Ai
Abstract read
In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Zebin Tong *School of Pharmaceutical Sciences, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, Center for Chemical Glycobiology-Zhangjiang Institute for Advanced Study, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Research Center for Chemical Biology of Post-Translational Modifications, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-2062-7105 Rujing Yuan *New Cornerstone Science Laboratory, Tsinghua-Peking Joint Center for Life Sciences, Ministry of Education Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Center for Synthetic and Systems Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China.
Xiangwei Wu *New Cornerstone Science Laboratory, Tsinghua-Peking Joint Center for Life Sciences, Ministry of Education Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Center for Synthetic and Systems Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China.ORCID 0009-0002-9367-8306 Hongyi CaiNew Cornerstone Science Laboratory, Tsinghua-Peking Joint Center for Life Sciences, Ministry of Education Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Center for Synthetic and Systems Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China.
Ziyu XuNew Cornerstone Science Laboratory, Tsinghua-Peking Joint Center for Life Sciences, Ministry of Education Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Center for Synthetic and Systems Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China.
Lei LiuNew Cornerstone Science Laboratory, Tsinghua-Peking Joint Center for Life Sciences, Ministry of Education Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Center for Synthetic and Systems Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, China. lliu@mail.tsinghua.edu.cn.ORCID 0000-0001-6290-8602 Huasong AiSchool of Pharmaceutical Sciences, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, Center for Chemical Glycobiology-Zhangjiang Institute for Advanced Study, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Research Center for Chemical Biology of Post-Translational Modifications, Shanghai Jiao Tong University, Shanghai, China. huasongai@sjtu.edu.cn.ORCID 0000-0002-3378-5874 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The giant E2-E3 chimera BIRC6 specifically engages ubiquitin-activating E1 enzyme UBA6, but not UBA1, enabling UBA6 to transfer activated ubiquitin to BIRC6, which then ubiquitinates downstream substrates such as caspases to regulate apoptosis. However, the molecular mechanism that underlies UBA6-mediated specific engagement of BIRC6 remains elusive. Here we use a Ub
Indexed as
Inhibitor of Apoptosis ProteinsUbiquitinUbiquitin-Activating EnzymesHumansModels, MolecularProtein BindingUbiquitinationBIRC6 protein, humanInhibitor of Apoptosis ProteinsUBA1 protein, humanUBA6 protein, humanUbiquitinUbiquitin-Activating Enzymes
Identifiers
PMID42811028
PMCPMC13623948
What OpenQuestion holds
Textmetadata
Read underepoch 390